

The PI3K/AKT/mTOR pathway in breast cancer: targets

Therapeutic Advances in Medical Oncology
6, 154-166

DOI: 10.1177/1758834014530023

Citation Report

#	ARTICLE	IF	CITATIONS
1	Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-8.	1.2	12
2	Overexpression of sorcin in multidrug-resistant human breast cancer. Oncology Letters, 2014, 8, 2393-2398.	1.8	18
3	Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. Cellular Signalling, 2014, 26, 2782-2792.	3.6	39
4	PIK3CA Mutations in Small Bowel Adenocarcinoma. Tumori, 2015, 101, e85-e87.	1.1	2
5	CaCO3/CalP6 composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth. International Journal of Nanomedicine, 2015, 10, 4255.	6.7	14
6	PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. Drug Design, Development and Therapy, 2015, 9, 4631.	4.3	6
7	Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions. Current Molecular Pharmacology, 2015, 7, 4-21.	1.5	23
8	Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor–positive advanced breast cancer. OncoTargets and Therapy, 2015, 8, 3629.	2.0	13
9	Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells. Oncology Research, 2015, 22, 193-201.	1.5	29
10	From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. Journal of Steroid Biochemistry and Molecular Biology, 2015, 153, 45-53.	2.5	47
11	Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway. BMC Cancer, 2015, 15, 958.	2.6	105
12	12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1 α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway. Oncology Reports, 2015, 34, 1755-1760.	2.6	29
13	Calycosin and Genistein Induce Apoptosis by Inactivation of HOTAIR/p-Akt Signaling Pathway in Human Breast Cancer MCF-7 Cells. Cellular Physiology and Biochemistry, 2015, 35, 722-728.	1.6	117
14	Impact of lower concentrations of phytoestrogens on the effects of estradiol in breast cancer cells. Climacteric, 2015, 18, 574-581.	2.4	16
15	PI3K/Akt signaling in osteosarcoma. Clinica Chimica Acta, 2015, 444, 182-192.	1.1	262
16	The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1. Breast Cancer Research and Treatment, 2015, 150, 105-118.	2.5	125
17	Curcumin Promotes Cell Cycle Arrest and Inhibits Survival of Human Renal Cancer Cells by Negative Modulation of the PI3K/AKT Signaling Pathway. Cell Biochemistry and Biophysics, 2015, 73, 681-686.	1.8	39
18	Molecular and diagnostic features of apocrine breast lesions. Expert Review of Molecular Diagnostics, 2015, 15, 1011-1022.	3.1	14

#	ARTICLE	IF	CITATIONS
19	Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opinion on Investigational Drugs, 2015, 24, 1045-1058.	4.1	1
20	Changing Treatment Paradigms in Metastatic Breast Cancer. JAMA Oncology, 2015, 1, 528.	7.1	88
21	Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2015, 153, 35-44.	2.5	90
22	MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy. Cell Reports, 2015, 11, 1358-1366.	6.4	40
23	Phosphatidylinositol-3-kinase as a putative target for anticancer action of clotrimazole. International Journal of Biochemistry and Cell Biology, 2015, 62, 132-141.	2.8	13
24	A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology, 2015, 35, S151-S184.	9.6	95
25	Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice. Journal of Endocrinology, 2015, 227, 143-151.	2.6	10
26	Localized experimental bone metastasis drives osteolysis and sensory hypersensitivity at distant non-tumor-bearing sites. Breast Cancer Research and Treatment, 2015, 153, 9-20.	2.5	10
27	Advances in small-molecule drug discovery for triple-negative breast cancer. Future Medicinal Chemistry, 2015, 7, 2019-2039.	2.3	14
28	Differential expression of epithelial-mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. Breast Cancer Research and Treatment, 2015, 154, 45-55.	2.5	32
29	The Genome Conformation As an Integrator of Multi-Omic Data: The Example of Damage Spreading in Cancer. Frontiers in Genetics, 2016, 7, 194.	2.3	22
30	FLIPL is critical for aerobic glycolysis in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2016, 35, 79.	8.6	17
31	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Frontiers in Pharmacology, 2016, 7, 395.	3.5	131
32	Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2016, 67, 182-190.	1.9	29
33	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. Cancer Drug Discovery and Development, 2016, , 109-124.	0.4	0
34	Discovery of 4-(Piperazin-1-yl)-7-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors. Archiv Der Pharmazie, 2016, 349, 356-362.	4.1	5
35	The PI3K Pathway: Background and Treatment Approaches. Breast Care, 2016, 11, 398-404.	1.4	28
36	Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives. Future Oncology, 2016, 12, 1517-1527.	2.4	9

#	ARTICLE	IF	CITATIONS
38	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2016, , 535-573.		0
39	Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2159-2171.	2.5	23
40	Effects of mutations in Wnt/ β -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activityâ€”Diverse effects on cell growth, metabolism and cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2942-2976.	4.1	137
41	Regulation of gene expression in human cancers by TRIM24. Drug Discovery Today: Technologies, 2016, 19, 57-63.	4.0	36
42	A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Medical Genomics, 2016, 9, 51.	1.5	42
43	Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Annals of Oncology, 2016, 27, 2059-2066.	1.2	79
44	Stiffness of the microenvironment upregulates ERBB2 expression in 3D cultures of MCF10A within the range of mammographic density. Scientific Reports, 2016, 6, 28987.	3.3	15
45	Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. Breast Cancer: Basic and Clinical Research, 2016, 10, BCBCR.S12443.	1.1	8
46	PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. Journal of Translational Medicine, 2016, 14, 67.	4.4	42
47	Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. Expert Opinion on Emerging Drugs, 2016, 21, 91-101.	2.4	26
48	Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 601-610.	3.8	26
49	Overexpression of Hexokinase 1 as a poor prognosticator in human colorectal cancer. Tumor Biology, 2016, 37, 3887-3895.	1.8	27
50	Pluripotency transcription factors in lung cancerâ€”a review. Tumor Biology, 2016, 37, 4241-4249.	1.8	24
51	mTORC1 directly phosphorylates and activates ER β upon estrogen stimulation. Oncogene, 2016, 35, 3535-3543.	5.9	70
52	Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2 β and ER+HER2+) breast cancers. Journal of Steroid Biochemistry and Molecular Biology, 2017, 170, 65-74.	2.5	26
53	Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies. Journal of Natural Products, 2017, 80, 932-952.	3.0	24
54	Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles. Endocrine-Related Cancer, 2017, 24, R81-R97.	3.1	21
55	A novel resveratrolâ€”salinomycin combination sensitizes ER-positive breast cancer cells to apoptosis. Pharmacological Reports, 2017, 69, 788-797.	3.3	24

#	ARTICLE	IF	CITATIONS
56	Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 487-497.	2.8	33
57	Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. <i>Future Oncology</i> , 2017, 13, 1371-1384.	2.4	5
58	Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4919-4928.	7.0	74
59	Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. <i>Genome Medicine</i> , 2017, 9, 40.	8.2	16
60	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017, 34, 119.	2.5	34
61	DNA Mutations May Not Be the Cause of Cancer. <i>Oncology and Therapy</i> , 2017, 5, 85-101.	2.6	48
62	Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 39-45.	5.6	13
63	Citrus flavonoid naringenin reduces mammary tumor cell viability, adipose mass, and adipose inflammation in obese ovariectomized mice. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600934.	3.3	44
64	Identification of natural allosteric inhibitor for Akt1 protein through computational approaches and in vitro evaluation. <i>International Journal of Biological Macromolecules</i> , 2017, 96, 200-213.	7.5	12
65	Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. <i>Cellular Signalling</i> , 2017, 30, 154-161.	3.6	32
66	Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?. <i>Drug Safety</i> , 2017, 40, 211-228.	3.2	11
67	Decreased levels of sRAGE in follicular fluid from patients with PCOS. <i>Reproduction</i> , 2017, 153, 285-292.	2.6	21
68	Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2017, 46, 158-181.	9.6	57
69	MicroRNA-218-5p as a Potential Target for the Treatment of Human Osteoarthritis. <i>Molecular Therapy</i> , 2017, 25, 2676-2688.	8.2	50
70	Controlling Directed Protein Interaction Networks in Cancer. <i>Scientific Reports</i> , 2017, 7, 10327.	3.3	55
71	Association of breast cancer risk and the mTOR pathway in women of African ancestry in the Root of the Root Consortium. <i>Carcinogenesis</i> , 2017, 38, 789-796.	2.8	6
72	Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2862-2866.	1.8	6
73	Whey Protein Concentrate Renders MDA-MB-231 Cells Sensitive to Rapamycin by Altering Cellular Redox State and Activating GSK3 β /mTOR Signaling. <i>Scientific Reports</i> , 2017, 7, 15976.	3.3	16

#	ARTICLE	IF	CITATIONS
74	Revisiting the IGF-1R as a breast cancer target. <i>Npj Precision Oncology</i> , 2017, 1, .	5.4	75
75	Transcription factor-associated combinatorial epigenetic pattern reveals higher transcriptional activity of TCF7L2-regulated intragenic enhancers. <i>BMC Genomics</i> , 2017, 18, 375.	2.8	13
76	Identifying gene-gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts. <i>Human Genetics</i> , 2017, 136, 165-178.	3.8	11
77	Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway. <i>Medical Science Monitor</i> , 2017, 23, 4182-4191.	1.1	22
78	Biomarkers From Systems Biology and Omics Studies. , 2017, , 67-79.		0
79	Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer. <i>Journal of Breast Cancer</i> , 2017, 20, 321.	1.9	21
80	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 85.	4.1	25
81	Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. <i>Frontiers in Endocrinology</i> , 2017, 8, 173.	3.5	10
82	Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients. <i>PLoS ONE</i> , 2017, 12, e0174022.	2.5	12
83	Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	3.0	31
84	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5491-5524.	2.0	56
85	Determination of the Relative Efficacy of Eicosapentaenoic Acid and Docosahexaenoic Acid for Anti-Cancer Effects in Human Breast Cancer Models. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2607.	4.1	30
86	Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient. <i>Cureus</i> , 2017, 9, e1408.	0.5	10
87	The influence of matrix stiffness on the behavior of brain metastatic breast cancer cells in a biomimetic hyaluronic acid hydrogel platform. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 1832-1841.	4.0	36
88	Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 499-506.	2.5	14
89	SRT1720, a potential sensitizer for radiotherapy and cytotoxicity effects of NVB-BE235 in metastatic breast cancer cells. <i>Pathology Research and Practice</i> , 2018, 214, 889-895.	2.3	17
90	The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells. <i>Breast Cancer Research</i> , 2018, 20, 16.	5.0	88
91	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. <i>Npj Precision Oncology</i> , 2018, 2, 7.	5.4	107

#	ARTICLE	IF	CITATIONS
92	Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 29-36.	4.4	35
93	Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. <i>Clinical Cancer Research</i> , 2018, 24, 395-406.	7.0	18
94	Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. <i>Cancer Treatment Reviews</i> , 2018, 62, 110-122.	7.7	273
95	The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. <i>PeerJ</i> , 2018, 6, e5092.	2.0	36
96	Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880850.	3.2	30
97	mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. <i>Npj Breast Cancer</i> , 2018, 4, 36.	5.2	20
98	Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis. <i>Scientific Reports</i> , 2018, 8, 16679.	3.3	29
99	Statins attenuate outgrowth of breast cancer metastases. <i>British Journal of Cancer</i> , 2018, 119, 1094-1105.	6.4	64
100	MiR-3188 Inhibits Non-small Cell Lung Cancer Cell Proliferation Through FOXO1-Mediated mTOR-p-PI3K/AKT-c-JUN Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2018, 9, 1362.	3.5	18
101	Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer. <i>BMC Systems Biology</i> , 2018, 12, 130.	3.0	7
102	C16- ϵ -ceramide and sphingosine-1-phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation. <i>Oncology Reports</i> , 2018, 40, 2977-2987.	2.6	9
103	Resveratrol provides neuroprotection by regulating the JAK2/STAT3/PI3K/AKT/mTOR pathway after stroke in rats. <i>Genes and Diseases</i> , 2018, 5, 245-255.	3.4	164
104	E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. <i>Scientific Reports</i> , 2018, 8, 15454.	3.3	55
105	Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	9
106	Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer. <i>Applied Biochemistry and Biotechnology</i> , 2018, 186, 1074-1089.	2.9	31
107	Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. <i>International Journal of Oncology</i> , 2018, 52, 2051-2060.	3.3	18
108	Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. <i>PLoS ONE</i> , 2018, 13, e0197422.	2.5	75
109	High collagen density augments mTOR-dependent cancer stem cells in ER α ++ mammary carcinomas, and increases mTOR-independent lung metastases. <i>Cancer Letters</i> , 2018, 433, 1-9.	7.2	29

#	ARTICLE	IF	CITATIONS
110	GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling. Scientific Reports, 2018, 8, 9511.	3.3	37
111	Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. Cancer Biology and Therapy, 2018, 19, 879-886.	3.4	22
112	Transcriptional repression of human epidermal growth factor receptor 2 by ClC ^{α3} /H ⁺ transporter inhibition in human breast cancer cells. Cancer Science, 2018, 109, 2781-2791.	3.9	16
113	Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K [±] -selective inhibitor CYH33 in breast cancer. Cancer Letters, 2018, 433, 273-282.	7.2	15
114	A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. Journal of Experimental and Clinical Cancer Research, 2018, 37, 12.	8.6	19
115	Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification. Cancer Research, 2018, 78, 6001-6010.	0.9	64
116	Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus. International Journal of Molecular Sciences, 2018, 19, 2310.	4.1	58
117	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Targeted Oncology, 2019, 14, 1-12.	3.6	12
118	Weighted Fused Pathway Graphical Lasso for Joint Estimation of Multiple Gene Networks. Frontiers in Genetics, 2019, 10, 623.	2.3	11
119	Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells. Molecular Biology Reports, 2019, 46, 4809-4816.	2.3	13
120	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
121	Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy. , 2019, , 449-462.		0
122	Targeting cellular cholesterol for anticancer therapy. FEBS Journal, 2019, 286, 4192-4208.	4.7	39
123	In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data. Scientific Reports, 2019, 9, 8949.	3.3	66
124	Gene relevance based on multiple evidences in complex networks. Bioinformatics, 2020, 36, 865-871.	4.1	6
125	Tamoxifen and Sulphoraphane for the breast cancer management: A synergistic nanomedicine approach. Medical Hypotheses, 2019, 132, 109379.	1.5	20
126	Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer. Cancer Genetics, 2019, 239, 36-45.	0.4	14
127	PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discovery Today, 2019, 24, 2181-2191.	6.4	170

#	ARTICLE	IF	CITATIONS
128	Investigation of Phospholipase C β 1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4721.	4.1	5
129	Bayesian Inference Identifies Combination Therapeutic Targets in Breast Cancer. IEEE Transactions on Biomedical Engineering, 2019, 66, 2684-2692.	4.2	26
130	Membrane metalloendopeptidase mediates cellular senescence induced by oncogenic PIK3CA ^{H1047R} accompanied with pro-tumorigenic secretome. International Journal of Cancer, 2019, 145, 817-829.	5.1	8
131	Expression analysis of miR-100 and selected genes from mTOR pathway in breast cancer patients. Meta Gene, 2019, 21, 100577.	0.6	1
132	HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment. Cell Cycle, 2019, 18, 1513-1522.	2.6	15
133	PI3K Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction. Journal of the American Heart Association, 2019, 8, e010961.	3.7	15
134	SP-8356, a (1S)-(E)-verbenone derivative, exerts in vitro and in vivo anti-breast cancer effects by inhibiting NF- κ B signaling. Scientific Reports, 2019, 9, 6595.	3.3	17
135	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. BMC Cancer, 2019, 19, 442.	2.6	26
136	Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer. International Journal of Molecular Sciences, 2019, 20, 1827.	4.1	14
137	Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer. Cancer Genomics and Proteomics, 2019, 16, 195-206.	2.0	13
138	The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. Cell Calcium, 2019, 79, 80-88.	2.4	46
139	Encircling the regions of the pharmacogenomic landscape that determine drug response. Genome Medicine, 2019, 11, 17.	8.2	14
140	Fomes fomentarius Ethanol Extract Exerts Inhibition of Cell Growth and Motility Induction of Apoptosis via Targeting AKT in Human Breast Cancer MDA-MB-231 Cells. International Journal of Molecular Sciences, 2019, 20, 1147.	4.1	15
142	Multilayer network analysis of miRNA and protein expression profiles in breast cancer patients. PLoS ONE, 2019, 14, e0202311.	2.5	8
143	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. Clinical Cancer Research, 2019, 25, 3374-3383.	7.0	57
144	Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells. Clinical Cancer Research, 2019, 25, 2900-2914.	7.0	24
145	Discovery, synthesis and molecular corroborations of medicinally important novel pyrazoles; drug efficacy determinations through in silico, in vitro and cytotoxicity validations. Bioorganic Chemistry, 2019, 86, 410-419.	4.1	18
146	Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation. Frontiers in Genetics, 2019, 10, 1047.	2.3	16

#	ARTICLE	IF	CITATIONS
147	Contribution of the unfolded protein response to breast and prostate tissue homeostasis and its significance to cancer endocrine response. <i>Carcinogenesis</i> , 2019, 40, 203-215.	2.8	15
148	Benefitâ€‘risk profile of black cohosh (isopropanolic <i>Cimicifuga racemosa</i> extract) with and without St Johnâ€™s wort in breast cancer patients. <i>Climacteric</i> , 2019, 22, 339-347.	2.4	25
149	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 29-42.	2.4	11
150	Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 489-497.	2.5	118
151	Systemic Treatment of HER2-Negative Metastatic Breast Cancer. , 2019, , 483-508.		0
152	Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A new look at hallmarks of breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 10080-10100.	4.1	208
153	Long-term exposure to extremely low-dose of nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induce non-malignant breast epithelial cell transformation through activation of the $\alpha 9$ -nicotinic acetylcholine receptor-mediated signaling pathway. <i>Environmental Toxicology</i> , 2019, 34, 73-82.	4.0	18
154	Peptide Based Imaging Agents for HER2 Imaging in Oncology. <i>Molecular Imaging</i> , 2020, 19, 153601212096025.	1.4	11
155	Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer. <i>BMC Cancer</i> , 2020, 20, 676.	2.6	8
156	Profilin choreographs actin and microtubules in cells and cancer. <i>International Review of Cell and Molecular Biology</i> , 2020, 355, 155-204.	3.2	32
157	Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with $\beta 1$ -Integrin Emerges as a Key Factor for Breast Cancer Chemosensitization upon Collagen Type 1 Binding. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4956.	4.1	13
158	Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells. <i>Cell Death and Disease</i> , 2020, 11, 996.	6.3	4
159	New horizons in benzothiazole scaffold for cancer therapy: Advances in bioactivity, functionality, and chemistry. <i>Applied Materials Today</i> , 2020, 20, 100783.	4.3	25
160	Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer. <i>Cancer Communications</i> , 2020, 40, 422-434.	9.2	6
161	Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2020, 15, 723-732.	3.6	6
162	Cancer subtype classification and modeling by pathway attention and propagation. <i>Bioinformatics</i> , 2020, 36, 3818-3824.	4.1	28
163	Cotargeting β ET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 2824-2837.	5.1	6
164	A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2â€‘ Metastatic Breast Cancer. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-16.	1.2	33

#	ARTICLE	IF	CITATIONS
165	p-TSA.H ₂ O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer. <i>Bioorganic Chemistry</i> , 2020, 102, 104046.	4.1	17
166	The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer. <i>Oncogene</i> , 2020, 39, 3588-3603.	5.9	24
167	Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets. <i>Pathology Research and Practice</i> , 2020, 216, 152874.	2.3	8
168	Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2â€“Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. <i>Clinical Breast Cancer</i> , 2020, 20, e439-e449.	2.4	10
169	Is Lactate an Oncometabolite? Evidence Supporting a Role for Lactate in the Regulation of Transcriptional Activity of Cancer-Related Genes in MCF7 Breast Cancer Cells. <i>Frontiers in Oncology</i> , 2019, 9, 1536.	2.8	63
170	Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. <i>Prostate</i> , 2020, 80, 412-423.	2.3	9
171	Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms â€“ an update on the evidence. <i>Climacteric</i> , 2021, 24, 109-119.	2.4	22
172	Obesity-related protein biomarkers for predicting breast cancer risk: an overview of systematic reviews. <i>Breast Cancer</i> , 2021, 28, 25-39.	2.9	14
173	Landscape of clinically actionable mutations in breast cancer â€“ A cohort studyâ€™™. <i>Translational Oncology</i> , 2021, 14, 100877.	3.7	4
174	miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway. <i>Bioscience Reports</i> , 2021, 41, .	2.4	11
175	siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line. <i>Cancer Management and Research</i> , 2021, Volume 13, 1123-1133.	1.9	6
176	A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-18.	1.2	6
177	The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancerâ€™™ A Preliminary Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2061.	4.1	8
178	IP6K2 predicts favorable clinical outcome of primary breast cancer. <i>Molecular and Clinical Oncology</i> , 2021, 14, 94.	1.0	2
179	Differential methylation and expression patterns of microRNAs in relation to breast cancer subtypes among American women of African and European ancestry. <i>PLoS ONE</i> , 2021, 16, e0249229.	2.5	8
180	High expression levels of centromere protein A plus upregulation of the phosphatidylinositol 3â€™kinase/Akt/mammalian target of rapamycin signaling pathway affect chemotherapy response and prognosis in patients with breast cancer. <i>Oncology Letters</i> , 2021, 21, 410.	1.8	17
181	Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer. <i>Frontiers in Endocrinology</i> , 2021, 12, 599586.	3.5	44
182	Cell specific tumor suppressor effect of Hsa-miR-1226-3p through downregulation of HER2, PIK3R2, and AKT1 genes. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 134, 105965.	2.8	10

#	ARTICLE	IF	CITATIONS
183	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesisâ€”New insight and futuristic vision. International Journal of Biological Macromolecules, 2021, 180, 739-752.	7.5	39
184	Stem cell therapy: A paradigm shift in breast cancer treatment. World Journal of Stem Cells, 2021, 13, 841-860.	2.8	8
185	Collagen XVII inhibits breast cancer cell proliferation and growth through deactivation of the AKT/mTOR signaling pathway. PLoS ONE, 2021, 16, e0255179.	2.5	16
186	Single-cell immunoblotting resolves estrogen receptor- α isoforms in breast cancer. PLoS ONE, 2021, 16, e0254783.	2.5	5
187	Efficacy and safety of long-term sirolimus use as part of multidisciplinary care in a pediatric patient with CLOVES syndrome: Case report. Translational Science of Rare Diseases, 2022, 6, 25-32.	1.5	0
188	COMPREHENSIVE REVIEW ON ETIOPATHOGENESIS, TREATMENT AND EMERGING THERAPIES OF BREAST CANCER. Asian Journal of Pharmaceutical and Clinical Research, 0, , 20-33.	0.3	0
189	Identification of a novel inhibitor of liver cancer cell invasion and proliferation through regulation of Akt and Twist1. Scientific Reports, 2021, 11, 16765.	3.3	3
190	Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial. Frontiers in Immunology, 2021, 12, 669965.	4.8	16
191	Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer. Cancers, 2021, 13, 4685.	3.7	34
193	Mangifera indica (Mango): A Promising Medicinal Plant for Breast Cancer Therapy and Understanding Its Potential Mechanisms of Action. Breast Cancer: Targets and Therapy, 2021, Volume 13, 471-503.	1.8	19
194	Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition. Cancer Cell International, 2021, 21, 515.	4.1	5
195	Network Pharmacology-Based Dissection of the Comprehensive Molecular Mechanisms of the Herbal Prescription FDY003 Against Estrogen Receptor-Positive Breast Cancer. Natural Product Communications, 2021, 16, 1934578X2110443.	0.5	1
196	Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Npj Breast Cancer, 2021, 7, 118.	5.2	3
197	Molecular Mechanisms Underlying Breast Cancer and Role of Plant Products in Targeted Therapy. , 2021, , 295-351.		3
198	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	28.4	141
199	Phytotherapy for breast cancer. , 2021, , 129-163.		5
200	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer: Basic and Clinical Research, 2021, 15, 117822342199585.	1.1	22
201	A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. Cancer Treatment and Research Communications, 2021, 29, 100457.	1.7	5

#	ARTICLE	IF	CITATIONS
203	In silico molecular docking studies and MM/GBSA analysis of coumarin-carbonodithioate hybrid derivatives divulge the anticancer potential against breast cancer. Beni-Suef University Journal of Basic and Applied Sciences, 2020, 9, .	2.0	58
204	P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2017, 12, e0170302.	2.5	5
205	Functional role of vitronectin in breast cancer. PLoS ONE, 2020, 15, e0242141.	2.5	16
206	Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer. Uspehi Molekularnoj Onkologii, 2018, 5, 40-50.	0.3	6
207	Lactobacilli Differentially Modulate mTOR and Wnt/ β -Catenin Pathways in Different Cancer Cell Lines. Iranian Journal of Cancer Prevention, 2016, In Press, e5369.	0.7	28
208	miR-623 suppresses cell proliferation, migration and invasion through direct inhibition of XRCC5 in breast cancer. Aging, 2020, 12, 10246-10258.	3.1	16
209	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget, 2016, 7, 55083-55097.	1.8	31
210	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. Oncotarget, 2016, 7, 60712-60722.	1.8	103
211	Transcriptional signature of lymphoblastoid cell lines of <i>BRCA1</i> and <i>BRCA2</i> and non- <i>BRCA1/2</i> high risk breast cancer families. Oncotarget, 2017, 8, 78691-78712.	1.8	8
212	Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Oncotarget, 2015, 6, 22081-22097.	1.8	20
213	Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells. Oncotarget, 2015, 6, 29637-29650.	1.8	65
214	Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget, 2016, 7, 6891-6901.	1.8	63
215	Expression of Bioinformatically Candidate miRNAs including, miR-576-5p, miR-501-3p and miR-3143, Targeting PI3K Pathway in Triple-Negative Breast Cancer. , 2019, 8, 1646.		4
216	[Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy–©AKT/m-TOR Pathway and Resistance to Cancer Therapy]. Chinese Journal of Lung Cancer, 2018, 21, 63-66.	0.7	6
217	miR-31 may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC. Experimental and Therapeutic Medicine, 2020, 19, 375-383.	1.8	11
218	Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World Journal of Clinical Oncology, 2018, 9, 172-179.	2.3	9
219	Dexamethasone Disrupts Cytoskeleton Organization and Migration of T47D Human Breast Cancer Cells by Modulating the AKT/mTOR/RhoA Pathway. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10245-10250.	1.2	19
220	PI3K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer. Re:GEN Open, 2021, 1, 83-91.	0.2	2

#	ARTICLE	IF	CITATIONS
221	New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects. Pharmaceuticals, 2021, 14, 1068.	3.8	27
222	A Network Pharmacology Analysis of the Systems-Perspective Anticancer Mechanisms of the Herbal Drug FDY2004 for Breast Cancer. Natural Product Communications, 2021, 16, 1934578X2110491.	0.5	0
223	Evaluating the influence of Human Umbilical Cord Mesenchymal Stem Cells-derived exosomes loaded with miR-3182 on metastatic performance of Triple Negative Breast Cancer cells. Life Sciences, 2021, 286, 120015.	4.3	24
224	THE ROLE OF PHOSPHATIDYLINOSITOL-3-KINASE IN CARCINOGENESIS. Voprosy Onkologii, 2017, 63, 545-556.	0.2	1
226	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2019, , 463-494.		0
228	Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer. Molecular Medicine Reports, 2019, 20, 2493-2499.	2.4	5
230	Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study. Journal of Biochemical and Molecular Toxicology, 2022, 36, e22938.	3.0	24
231	Pericardial Effusion Caused by an mTOR Inhibitor in a Case of Recurrent Breast Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2020, 45, 209-213.	0.0	0
233	PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 8295-303.	0.5	18
234	MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 368-73.	0.5	16
236	Alnustone inhibits the growth of hepatocellular carcinoma via ROS-mediated PI3K/Akt/mTOR/p70S6K axis. Phytotherapy Research, 2022, 36, 525-542.	5.8	7
237	Beneficial Oxidative Stress-Related trans-Resveratrol Effects in the Treatment and Prevention of Breast Cancer. Applied Sciences (Switzerland), 2021, 11, 11041.	2.5	12
238	miR-130b suppresses the invasion and migration of prostate cancer via inhibiting DLL1 and regulating the PI3K/Akt pathways. Experimental and Therapeutic Medicine, 2021, 23, 98.	1.8	5
239	Lasiosiphon glaucus a potent ethnobotanical medicinal plant against breast cancer targeting multiple pathways: an invitro study. Advances in Traditional Medicine, 0, , 1.	2.0	0
240	A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast, 2022, 61, 156-167.	2.2	12
241	Nuances of PFKFB3 Signaling in Breast Cancer. Clinical Breast Cancer, 2022, 22, e604-e614.	2.4	13
244	Rumex Vesicarius L. extract improves the efficacy of doxorubicin in triple-negative breast cancer through inhibiting Bcl2, mTOR, JNK1 and augmenting p21 expression. Informatics in Medicine Unlocked, 2022, 29, 100869.	3.4	18
245	Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. Integrative Cancer Therapies, 2022, 21, 153473542110731.	2.0	3

#	ARTICLE	IF	CITATIONS
246	Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature. <i>Cureus</i> , 2022, 14, e21970.	0.5	9
247	Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment. <i>Diagnostics</i> , 2022, 12, 394.	2.6	4
248	<i>In silico</i> Prediction on the PI3K/AKT/mTOR Pathway of the Antiproliferative Effect of <i>O. joconostle</i> in Breast Cancer Models. <i>Cancer Informatics</i> , 2022, 21, 117693512210870.	1.9	3
249	Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance. <i>Cardiology Research and Practice</i> , 2022, 2022, 1-14.	1.1	5
250	New and Emerging Targeted Therapies for Advanced Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2288.	4.1	55
251	The Complexity of Response to the Proliferation Agonist and Antagonist Agents, in the Breast Cancer Cell Lines with Various Receptors. <i>Iranian Journal of Pharmaceutical Research</i> , 2022, 21, .	0.5	0
252	Dual PI3K/Akt Inhibitors Bearing Coumarin-Thiazolidine Pharmacophores as Potential Apoptosis Inducers in MCF-7 Cells. <i>Pharmaceuticals</i> , 2022, 15, 428.	3.8	5
253	<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100370.	3.0	17
254	Clinical and molecular characteristics of estrogen receptor- α -positive ultralow risk breast cancer tumors identified by the 70-gene signature. <i>International Journal of Cancer</i> , 2022, 150, 2072-2082.	5.1	7
255	Plant Derived Bioactive Compounds, Their Anti-Cancer Effects and In Silico Approaches as an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview. <i>Cancers</i> , 2021, 13, 6222.	3.7	20
256	The Discovery of New Drug-Target Interactions for Breast Cancer Treatment. <i>Molecules</i> , 2021, 26, 7474.	3.8	8
258	Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 784985.	2.8	8
262	Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 66.	3.3	3
267	MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells. <i>Endocrine-Related Cancer</i> , 2022, 29, 451-465.	3.1	3
268	Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line. <i>Molecules</i> , 2022, 27, 3661.	3.8	10
269	Biom mineralization associated alkaline phosphatase as a potential marker of bone metastasis in the patients with invasive breast cancer. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 103340.	3.8	0
270	Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	25
271	Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. <i>Cancers</i> , 2022, 14, 3374.	3.7	2

#	ARTICLE	IF	CITATIONS
272	The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Military Medical Research, 2022, 9, .	3.4	5
273	Directed Evolution Enables Simultaneous Controlled Release of Multiple Therapeutic Proteins from Biopolymer-Based Hydrogels. Advanced Materials, 2022, 34, .	21.0	11
274	A Unified Bayesian Framework for Bi-overlapping-Clustering Multi-omics Data via Sparse Matrix Factorization. Statistics in Biosciences, 0, , .	1.2	0
275	Recent Advances in Synthesis and the Anticancer Activity of Benzothiazole Hybrids as Anticancer Agents. , 2022, , 105-166.		0
276	âŸ•äºŽâ•Ÿ»†èfžæ•°æ@çš,,ç™Œç—†ââŒÉ©±âŠ•æ”†â•—è†â^«æ—¹æ³•. Scientia Sinica Informationis, 2022, , .	0.4	0
278	Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. Biomedicines, 2022, 10, 1914.	3.2	5
279	Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness. Frontiers in Endocrinology, 0, 13, .	3.5	8
280	XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer. Biomedicine and Pharmacotherapy, 2022, 155, 113537.	5.6	9
281	Redox Signaling. , 2022, , 3435-3455.		0
282	Mechanistic and Therapeutic Crosstalk of Lipid Peroxidation in Oxidative Stress and Breast Cancer. , 2022, , 3457-3475.		0
283	Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Cancers, 2022, 14, 4234.	3.7	2
284	SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	1
285	<scp>6â€Methoxydihydrosanguinarine</scp> induces apoptosis and autophagy in breast cancer <scp>MCF</scp>â€7 cells by accumulating <scp>ROS</scp> to suppress the <scp>PI3K</scp>/<scp>AKT</scp>/<scp>mTOR</scp> signaling pathway. Phytotherapy Research, 2023, 37, 124-139.	5.8	6
286	Understanding the Polyamine and mTOR Pathway Interaction in Breast Cancer Cell Growth. Medical Sciences (Basel, Switzerland), 2022, 10, 51.	2.9	7
287	A Potential Anticancer Mechanism of Finger Root (Boesenbergia rotunda) Extracts against a Breast Cancer Cell Line. Scientifica, 2022, 2022, 1-17.	1.7	5
288	Myokines derived from contracting skeletal muscle suppress anabolism in MCF7 breast cancer cells by inhibiting mTOR. Frontiers in Physiology, 0, 13, .	2.8	3
289	Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway. , 2022, 39, .		12
290	Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer. Cancers, 2022, 14, 4878.	3.7	4

#	ARTICLE	IF	CITATIONS
291	mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12470.	4.1	6
292	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. <i>Cancers</i> , 2022, 14, 5206.	3.7	14
293	Predicting clinical response to everolimus in ER+ breast cancers using machine-learning. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	1
295	Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients. <i>Heliyon</i> , 2022, , e11396.	3.2	0
296	LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway. <i>Cancer Biology and Therapy</i> , 2022, 23, 1-13.	3.4	7
297	Evaluation of 68Ga-Radiolabeled Peptides for HER2 PET Imaging. <i>Diagnostics</i> , 2022, 12, 2710.	2.6	1
298	Network pharmacology based investigation on the mechanism of tetrandrine against breast cancer. <i>Phytomedicine Plus</i> , 2023, 3, 100381.	2.0	0
299	The combination of <i>Elephantopus scaber</i> and <i>Phaleria macrocarpa</i> leaves extract promotes anticancer activity via downregulation of ER- α , Nrf2 and PI3K/AKT/mTOR pathway. <i>Journal of Ayurveda and Integrative Medicine</i> , 2022, 13, 100674.	1.7	1
302	Investigating the Function of Human Jumping Translocation Breakpoint Protein (hJTB) and Its Interacting Partners through In-Solution Proteomics of MCF7 Cells. <i>Molecules</i> , 2022, 27, 8301.	3.8	5
303	Cancer Stem Cells—The Insight into Non-Coding RNAs. <i>Cells</i> , 2022, 11, 3699.	4.1	2
304	Synthesis, molecular docking, and in-vitro studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS/PI3K/Akt/JNK inhibition in breast carcinoma cells. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
305	<scp>RM12</scp> is a novel prognostic and predictive biomarker for breast cancer. <i>Cancer Medicine</i> , 2023, 12, 8331-8350.	2.8	3
306	PI3K—AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. <i>Biomolecules</i> , 2023, 13, 93.	4.0	16
307	OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	6
308	Using publicly available datasets to identify population-based transcriptomic landscape contributing to the aggressiveness of breast cancer in young women. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
309	Combination of Conventional Drugs with Biocompounds Derived from Cinnamic Acid: A Promising Option for Breast Cancer Therapy. <i>Biomedicines</i> , 2023, 11, 275.	3.2	5
310	Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway <i>in vitro</i> and <i>in vivo</i>. <i>Acta Pharmaceutica</i> , 2023, 73, 75-90.	2.0	1
311	Upstreaming and Downstreaming Regulators and Associated Signaling Transduction Pathways of AKT/PKB: A Molecular Gateway to Progressive Carcinoma. <i>Asian Journal of Biology</i> , 0, , 8-15.	0.3	0

#	ARTICLE	IF	CITATIONS
312	Brazilein inhibits epithelial-mesenchymal transition (EMT) and programmed death ligand 1 (PD-L1) expression in breast cancer cells. <i>International Immunopharmacology</i> , 2023, 118, 109988.	3.8	1
313	Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. <i>Biochemical Pharmacology</i> , 2023, 212, 115545.	4.4	8
314	Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis. <i>Life Sciences</i> , 2023, 323, 121662.	4.3	6
315	Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. <i>Cancers</i> , 2023, 15, 1320.	3.7	13
316	Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
317	Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. <i>Cancers</i> , 2023, 15, 1582.	3.7	4
318	Proteomics analysis of human breast milk by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled with mass spectrometry to assess breast cancer risk. <i>Electrophoresis</i> , 2023, 44, 1097-1113.	2.4	1
319	Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. <i>Investigational New Drugs</i> , 0, , .	2.6	0
320	Anthocyanins Reduce Cell Invasion and Migration through Akt/mTOR Downregulation and Apoptosis Activation in Triple-Negative Breast Cancer Cells: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 2300.	3.7	2
322	Nanomedicine Technologies for Diagnosis and Treatment of Breast Cancer. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 671-682.	4.9	7
323	Dietary Supplementation of Inulin Contributes to the Prevention of Estrogen Receptor-Negative Mammary Cancer by Alteration of Gut Microbial Communities and Epigenetic Regulations. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9015.	4.1	3
324	Mir-183 functions as an oncogene via decreasing PTEN in breast cancer cells. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
325	An Immunohistochemical Study of Breast Cancer Brain Metastases: The Role of CD44 and AKT in the Prognosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2023, 31, 318-323.	1.2	0
326	Thiol redox proteomics: Characterization of thiol-based post-translational modifications. <i>Proteomics</i> , 2023, 23, .	2.2	3
327	Uncharacterized Proteins CxORFx: Subinteractome Analysis and Prognostic Significance in Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10190.	4.1	0
328	SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 1479-1486.	2.0	2
329	The Potential of Stem Cells in Treating Breast Cancer. <i>Current Stem Cell Research and Therapy</i> , 2024, 19, 324-333.	1.3	0
330	Interplay between LncRNAs and microRNAs in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8095.	4.1	10

#	ARTICLE	IF	CITATIONS
331	Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer. <i>Biology</i> , 2023, 12, 697.	2.8	3
332	Effect of Smilax spp. and Phellinus linteus combination on cytotoxicity and cell proliferation of breast cancer cells. <i>BMC Complementary Medicine and Therapies</i> , 2023, 23, .	2.7	2
333	Preconditioned Chorionic Villus Mesenchymal Stem/Stromal Cells (CVMSCs) Minimize the Invasive Phenotypes of Breast Cancer Cell Line MDA231 In Vitro. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9569.	4.1	1
334	Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10910.	4.1	3
335	Dysfunction of ubiquitin protein ligase <i>MYCBP2</i> leads to cell resilience in human breast cancers. <i>NAR Cancer</i> , 2023, 5, .	3.1	0
336	Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment. , 2023, 40, .		7
337	Plasma microRNA ratios associated with breast cancer detection in a nested caseâ€“control study from a mammography screening cohort. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
338	Houttuynia cordata Thunb. Hexane fraction induces MDA-MB-231 cell apoptosis via caspases, ER stress, cell cycle arrest and attenuated Akt/ERK signaling. <i>Heliyon</i> , 2023, 9, e18755.	3.2	1
339	Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives. <i>Cells</i> , 2023, 12, 2014.	4.1	1
340	Evaluation of [⁸⁹ Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer. <i>Molecular Pharmaceutics</i> , 2023, 20, 4629-4639.	4.6	1
341	Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-Î², and MAPK signaling pathways during breast tumor progression. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	5
342	Anti-breast cancer activity of bioactive metabolites from <i>Andrographis paniculata</i> through inhibition of PI3K activity in triple negative breast cancer (MDA-MB-231) cells. <i>Journal of Molecular Structure</i> , 2023, , 136506.	3.6	2
343	Dysregulation of Cholesterol Homeostasis in Ovarian Cancer. <i>Current Oncology</i> , 2023, 30, 8386-8400.	2.2	0
344	Impact of Surface Charge-Tailored Gold Nanorods for Selective Targeting of Mitochondria in Breast Cancer Cells Using Photodynamic Therapy. <i>ACS Omega</i> , 2023, 8, 33229-33241.	3.5	1
345	Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14256.	4.1	1
346	<i>Streptococcus mitis</i> and <i>Prevotella melaninogenica</i> Influence Gene Expression Changes in Oral Mucosal Lesions in Periodontitis Patients. <i>Pathogens</i> , 2023, 12, 1194.	2.8	0
348	Targeted therapies against breast cancer: Clinical perspectives, obstacles and new opportunities. <i>Journal of Drug Delivery Science and Technology</i> , 2023, 89, 105049.	3.0	2
349	The Role of Obesity in Breast Cancer Pathogenesis. <i>Cells</i> , 2023, 12, 2061.	4.1	1

#	ARTICLE	IF	CITATIONS
350	Cellular responses in crustaceans under white spot syndrome virus infection. Fish and Shellfish Immunology, 2023, 140, 108984.	3.6	2
353	Computational examination to reveal Kaempferol as the most potent active compound from <i>Euphorbia hirta</i> against breast cancer by targeting AKT1 and ER1 α . Egyptian Journal of Basic and Applied Sciences, 2023, 10, 753-767.	0.6	0
354	mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers. Breast Cancer Research, 2023, 25, .	5.0	0
355	Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer. Lipids in Health and Disease, 2023, 22, .	3.0	1
356	AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLoS ONE, 2023, 18, e0294065.	2.5	2
357	NETWORK PHARMACOLOGY, APOPTOSIS, AND CELL CYCLE INHIBITION OF SESQUITERPENE COMPOUNDS FROM QUSTHUL HINDI ROOT EXTRACT (SAUSSUREA LAPPA) IN BREAST CANCER: AN IN SILICO AND IN VITRO APPROACH. International Journal of Applied Pharmaceutics, 0, , 132-141.	0.3	0
358	Oncolytic Virotherapy Against Breast Cancer. , 2023, , .		0
359	MLLT11 siRNA Inhibits the Migration and Promotes the Apoptosis of MDA-MB-231 Breast Cancer Cells. Breast Journal, 2023, 2023, 1-11.	1.0	0
360	Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors. BMC Cancer, 2023, 23, .	2.6	0
361	Breast Cancer Treatment: To tARget or Not? That Is the Question. Cancers, 2023, 15, 5664.	3.7	0
362	TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review. Frontiers in Oncology, 0, 13, .	2.8	0
363	Cardiotoxicity of Chemotherapy in Lynch Syndrome – A Literature Review. , 0, 126, 3-11.		0
364	LncRNA MALAT1 Expression Regulates Breast Cancer Progression via PI3K/AKT/mTOR Pathway Modulation. Biochemical Genetics, 0, , .	1.7	0
365	Integration of phosphoinositide 3-kinase (PI3K) and transforming growth factor β 1 (TGF- β 1) signaling cascades: role in the therapeutic inefficiency of tamoxifen. Uspehi Molekularnoj Onkologii, 2023, 10, 47-60.	0.3	0
366	The potential relevance of long non-coding RNAs in colorectal cancer pathogenesis and treatment: A review focus on signaling pathways. Pathology Research and Practice, 2024, 253, 155044.	2.3	0
367	An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?. Expert Review of Neurotherapeutics, 2024, 24, 77-103.	2.8	0
368	Network pharmacology, molecular docking and molecular dynamics simulation of chalcone scaffold-based compounds targeting breast cancer receptors. Journal of Biomolecular Structure and Dynamics, 0, , 1-16.	3.5	0
369	Anti-breast cancer potential analysis of phytochemicals in Selaginella doederleinii Hieron ethanolic extract through in silico study. AIP Conference Proceedings, 2023, , .	0.4	0

#	ARTICLE	IF	CITATIONS
370	Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of PI3K/AKT/mTOR pathway in triple-negative breast cancer cells. , 2024, 41, .		0
371	The determinants of metabolic discrepancies in aerobic glycolysis: Providing potential targets for breast cancer treatment. Biochimie, 2024, 220, 107-121.	2.6	0
373	Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells. International Journal of Molecular Sciences, 2024, 25, 1783.	4.1	0
374	Investigation on the structural and dynamical properties of cationic, anionic, and catanionic niosomes as multifunctional controlled drug delivery system for cabozantinib. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2024, 687, 133547.	4.7	0
375	Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol. Nutrients, 2024, 16, 708.	4.1	0
376	Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer. Surgical Oncology, 2024, 54, 102060.	1.6	0
378	Natural Compounds and Breast Cancer: Chemo-Preventive and Therapeutic Capabilities of Chlorogenic Acid and Cinnamaldehyde. Pharmaceuticals, 2024, 17, 361.	3.8	0